immuno-oncology

News

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

01/29/2020

            – Application is being reviewed under FDA's Real-Time Oncology Review pilot program – SOUTH SAN FRANCISCO, Calif. – January 26, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:...

       ...

01/29/2020

IO Learning

News

FDA Approves Combination Immunotherapy for Renal Cell Carcinoma

04/17/2018

The FDA has approved the combination of nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) to treat intermediate- or poor-risk advanced renal cell carcinoma that was previously untreated. The approval is based on data...

The FDA has approved the...

04/17/2018

IO Learning

News

HalioDx performed development work for ipsogen® JAK2 510(k) clearance by QIAGEN

03/30/2017

Marseille, France, March 30, 2017 - HalioDx SAS, an immuno-oncology diagnostic company, today announced that its R&D collaboration with QIAGEN N.V., a leading global provider of Sample to Insight solutions, has resulted in a U.S. Food and...

Marseille, France, March 30,...

03/30/2017

IO Learning

Interview

Immunotherapies and the Future of Cancer Care

03/08/2016

Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...

Five...

03/08/2016

Journal of Clinical Pathways

Research in Review

Suicide Gene Therapy Safe and Effective in Treating Prostate Cancer

12/15/2015

JCP Editors

A long-term clinical trial of suicide gene therapy has shown that it safely and effectively destroys prostate cancer cells. The method alters the genetic composition of cancer cells so that they trigger the immune...

A...

12/15/2015

Journal of Clinical Pathways